These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 16098285)

  • 1. First- and second-generation antipsychotic medication and cognitive processing in schizophrenia.
    Weickert TW; Goldberg TE
    Curr Psychiatry Rep; 2005 Aug; 7(4):304-10. PubMed ID: 16098285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia.
    Woodward ND; Jayathilake K; Meltzer HY
    Schizophr Res; 2007 Feb; 90(1-3):86-96. PubMed ID: 17123785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catechol-O-methyl transferase and schizophrenia.
    Sagud M; Mück-Seler D; Mihaljević-Peles A; Vuksan-Cusa B; Zivković M; Jakovljević M; Pivac N
    Psychiatr Danub; 2010 Jun; 22(2):270-4. PubMed ID: 20562760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications.
    Weickert TW; Goldberg TE; Mishara A; Apud JA; Kolachana BS; Egan MF; Weinberger DR
    Biol Psychiatry; 2004 Nov; 56(9):677-82. PubMed ID: 15522252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment.
    Spellmann I; Riedel M; Städtler J; Zill P; Obermeier M; Cerovecki A; Dehning S; Schennach R; Epple M; Opgen-Rhein M; Müller N; Bondy B; Möller HJ; Musil R
    Cogn Neuropsychiatry; 2017 Jul; 22(4):280-297. PubMed ID: 28470106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia.
    Illi A; Kampman O; Hänninen K; Anttila S; Mattila KM; Katila H; Rontu R; Hurme M; Lehtimäki T; Leinonen E
    Hum Psychopharmacol; 2007 Jun; 22(4):211-5. PubMed ID: 17526059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.
    Jann MW
    Pharmacotherapy; 2004 Dec; 24(12):1759-83. PubMed ID: 15585443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS?
    Weiser M; Shneider-Beeri M; Nakash N; Brill N; Bawnik O; Reiss S; Hocherman S; Davidson M
    Schizophr Res; 2000 Dec; 46(2-3):81-9. PubMed ID: 11120419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics.
    Spellmann I; Müller N; Musil R; Zill P; Douhet A; Dehning S; Cerovecki A; Bondy B; Möller HJ; Riedel M
    Eur Arch Psychiatry Clin Neurosci; 2008 Sep; 258(6):335-44. PubMed ID: 18347838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.
    Bertolino A; Caforio G; Blasi G; De Candia M; Latorre V; Petruzzella V; Altamura M; Nappi G; Papa S; Callicott JH; Mattay VS; Bellomo A; Scarabino T; Weinberger DR; Nardini M
    Am J Psychiatry; 2004 Oct; 161(10):1798-805. PubMed ID: 15465976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.
    Levin ED; Rezvani AH
    Biochem Pharmacol; 2007 Oct; 74(8):1182-91. PubMed ID: 17714691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds.
    Weickert TW; Goldberg TE; Marenco S; Bigelow LB; Egan MF; Weinberger DR
    Neuropsychopharmacology; 2003 Aug; 28(8):1491-500. PubMed ID: 12799617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
    Cuesta MJ; Peralta V; Zarzuela A
    Schizophr Res; 2001 Mar; 48(1):17-28. PubMed ID: 11278151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of cognitive dysfunction in schizophrenia.
    Peuskens J; Demily C; Thibaut F
    Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial.
    Albert N; Randers L; Allott K; Jensen HD; Melau M; Hjorthøj C; Nordentoft M
    Psychol Med; 2019 May; 49(7):1138-1147. PubMed ID: 30058511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact on cognition of the use of antipsychotics.
    Sharma T
    Curr Med Res Opin; 2002; 18 Suppl 3():s13-7. PubMed ID: 12418607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.